- All
- Product Management
- News and Information
- Introduction content
- Enterprise outlets
- Frequently Asked Questions
- Corporate Video
- Company Portfolio
Highlights of G20: The only Argentine company that produces foot-and-mouth disease vaccine in China
Release time:
2019-06-27 15:47
Tomorrow (June 3), the G20 Agriculture Ministers' Meeting will be held in Xi'an. Jinhai Biotechnology Co., Ltd., one of the official visiting routes, is particularly attractive. It is a Chinese foot-and-mouth disease vaccine manufacturer with vaccines. Production was previously administered by Biogenesis Bago, a member of the Sigman and Bago families. Jinhai Biotechnology Co., Ltd. is a public-private joint venture established by Haili Biotechnology Co., Ltd. and Biogenesis Bago. It is located in Yangling, the center of the advanced technology of the world's agricultural projects. At that time, Argentine Minister of Agriculture Ricardo Buryayile will also come to the meeting.
Biogenesis Bago general manager Guillermo Mattioli said in an interview that the production base in China can produce 400 million doses of foot-and-mouth disease vaccine. “The aim is to strategically support China's food production and biosecurity in pork and dairy products.”
At the G20 First Agricultural Entrepreneurs Summit and the Ministers of Agriculture, Guillermo Mattioli pointed out that based on the experience of Biogenesis Bago, Bioceres and Garruchos Agropecuaria, which are mainly dedicated to biotechnology innovation, will also join the ranks. He predicted that within the framework of the bilateral agreement between the two governments, more companies will cooperate with China in the future, which is conducive to the exchange and transfer of science and technology, improve the production efficiency of crops and animal health, and take a strategic vision of sustainable development. To promote food safety.
In China, the foot-and-mouth disease vaccine production base was built in Yangling, the national agricultural and animal husbandry center. The project is titled “Yangling Jinhai Biotechnology Co., Ltd.”, its main shareholder Fang Haili Biotechnology Co., Ltd. holds 60% of the shares, and the remaining 40% is held by Biogenesis Bago. (Reporter Ma Chao)
inactivated vaccine